Back
Vertex Pharmaceuticals, Inc. 10K Form
Buy
55
VRTX
Vertex Pharmaceuticals, Inc.
Last Price:
$476.80
Seasonality Move:
4.65%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-07 | 10Q | VRTX/Vertex Pharmaceuticals, Inc. Quarterly |
| 2024-02-15 | 10K | VRTX/Vertex Pharmaceuticals, Inc. Annual |
| 2023-11-07 | 10Q | VRTX/Vertex Pharmaceuticals, Inc. Quarterly |
| 2023-08-02 | 10Q | VRTX/Vertex Pharmaceuticals, Inc. Quarterly |
| 2023-05-02 | 10Q | VRTX/Vertex Pharmaceuticals, Inc. Quarterly |
| 2023-02-10 | 10K | VRTX/Vertex Pharmaceuticals, Inc. Annual |
Receive VRTX News And Ratings
See the #1 stock for the next 7 days that we like better than VRTX
VRTX Financial Statistics
Sales & Book Value
| Annual Sales: | $12.1B |
|---|---|
| Cash Flow: | $348.6M |
| Price / Cash Flow: | 37.91 |
| Annual Sales: | $73.49 |
| Price / Book: | 6.39 |
Profitability
| EPS (TTM): | 15.33490 |
|---|---|
| Net Income (TTM): | $4B |
| Gross Margin: | $10.3B |
| Return on Equity: | 22.97% |
| Return on Assets: | 16.33% |
Vertex Pharmaceuticals, Inc. Earnings Forecast
Key Vertex Pharmaceuticals, Inc. Financial Ratios
-
The Gross Profit Margin over the past 35 years for VRTX is 85.03%.
-
The Selling, General & Administrative Expenses for VRTX have been equal to 14.52% of Gross Profit Margin.
-
The Research & Development expenses have been 31.09% of Revenue.
-
The Interest Expense is 0.34% of Operating Income.
-
The Net Earning history of VRTX is 32.74% of Total Revenues.
-
Per Share Earnings over the last 36 years have been positive in 15 years.
Vertex Pharmaceuticals, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | S&P500 |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | VRTX |
| CUSIP: | 92532F |
| Website: | vrtx.com |
Debt
| Debt-to-Equity Ratio: | 0.11 |
|---|---|
| Current Ratio: | 2.9 |
| Quick Ratio: | 2.24 |
Price-to-Earnings
| Trailing P/E Ratio: | 30.63 |
|---|---|
| Forward P/E Ratio: | 21.43 |
VRTX Technical Analysis vs Fundamental Analysis
Buy
55
Vertex Pharmaceuticals, Inc. (VRTX)
is a Buy
Is Vertex Pharmaceuticals, Inc. a Buy or a Sell?
-
Vertex Pharmaceuticals, Inc. stock is rated a BuyThe current Vertex Pharmaceuticals, Inc. [VRTX] share price is $476.90. The Score for VRTX is 55, which is 10% above its historic median score of 50, and infers lower risk than normal.